SAB Biotherapeutics, a Sioux Falls, S.D.-based clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, closed a $14m Series B funding round.
New investor, global healthcare leader Merck, known as MSD outside the United States and Canada, was joined by South Dakota Equity Partners and several other follow-on and private investors. With this Series B, the company has raised approximately $50m in equity and secured more than $100m in non-dilutive funding in the form of grants and contracts, since its
